Lung transplantation using RNA+ hepatitis C (HCV+) donors to seronegative recipients is not currently performed due to the very high risk of transmission. Previous reports have shown poor survival when this practice was applied. The emergence of new directacting antiviral drugs (DAA) suggests a high chance of sustained virologic response in immunocompetent patients. We report here successful transplantation of lungs from HCV+ donor to HCVÀ recipient. The recipient was an HCVÀ patient with chronic lung allograft dysfunction. Viral transmission occurred early posttransplant but excellent clinical outcomes were observed including elimination of HCV after 12 weeks of treatment using DAAs.
Introduction
Despite the increased frequency of lung transplants performed each year (1) , there are still an insufficient number of suitable donor lungs for the growing waiting list of patients with end-stage lung diseases. Consequently, waitlist mortality can be as high as 30% (2) . Thus, strategies to increase organ availability are of critical importance. About 130-150 million people globally are chronically infected with hepatitis C (HCV). The United States national registry data showed 3273 HCV+ deceased donors from 2005 through 2014 for whom organ donation was authorized in the United States, resulting in 2402 kidney transplants (3) . In some organ procurement organizations in North America, the prevalence of (HCV) infection among organ donors can be as high as 15-20% of the total donor pool and with the increased population of intravenous drug users that number continues to increase.
Due to a very high risk of transmission (%90%) (4), lungs from HCV+ donors are not offered for transplantation to HCVÀ recipients. Data available from HCVÀ recipients receiving lungs from HCV+ donors demonstrate a dismal prognosis likely related to toxic effects of previous HCV therapies but also due to pulmonary and systemic manifestations of HCV (5) . In a recent review of 16 604 HCVÀ patients in the United Network for Organ Sharing database, 28 (0.2%) received a lung from an HCV+ donor, with use of HCV+ donors decreasing significantly over time. Overall survival was markedly shorter in the HCV+ donor group (median survival: 1.3 vs 5.1 years; p = 0.002) (5).
The development of new direct-acting antiviral drugs (DAA) against HCV has provided an opportunity for reassessment of organ transplantation from HCV+ donors to HCVÀ recipients. In fact, a clinical trial in kidney transplantation has just commenced in the United States (ClinicalTrials.gov Identifier: NCT02781649) to assess the safety of this approach. Herein we report a successful intentional lung transplantation using an extended criteria HCV+ donor to a rapidly deteriorating recipient awaiting a second lung transplant.
Case

Patient
The patient, a 44-year-old man with a history of pulmonary fibrosis, underwent left single lung transplantation 3 years prior to this admission. Unfortunately, he developed chronic lung allograft dysfunction (restrictive subtype). He was assessed for the possibility of retransplant and his HCV serology was negative. He also tested negative for hepatitis B surface antibody (HBsAb) and hepatitis B surface antigen (HBsAg). He was listed for a second lung transplant 14 months after his initial transplant. His medical condition deteriorated with progressive increase in oxygen requirement; he was admitted and treated for possible pneumonia. Despite treatments his hypoxemic respiratory failure progressed to the point that he could not keep his oxygen saturation above 80% on 100% FiO 2 with Optiflow.
At this point, a deceased donor lung was offered to our team. However, the donor tested positive for HCV by nucleic acid testing (NAT). Given the recipient's imminent risk of death and the potential for direct-acting antiviral (DAA) treatment after transplantation, our team decided to consider this donor lung. The patient and his wife were fully informed of the risks of transmission and rapid progression of HCV given his immunosuppressed state, the effectiveness of DAA in nonimmunocompromised patients, and the unknown likelihood that this treatment would be approved for this untested indication by his provincial health insurance plan. Finally, the patient and family decided to accept this donor lung.
Donor
A 60-year-old male brain-death donor presented at the emergency department unresponsive with a clinical scenario compatible with a stroke. The computed tomography scan of the head revealed massive intracerebral hemorrhage. The donor had a smoking history of 40 pack-years, quitting 6 months prior to his death, as well as a history of cocaine use (snorted and intravenous) 33 years prior. He was known to be positive for HCV since 2014 and he was not being treated. His serology was also positive for cytomegalovirus IgG, Epstein Barr virus IgG and hepatitis B core antibody (HBsAb positive, HBsAg negative, NAT negative).
The chest radiograph showed bilateral infiltration compatible with pulmonary edema. Bronchoscopy showed mild, nonrecurrent, mucoid secretions. Arterial blood gas on fraction of inspired oxygen (FIO2) 1.0 and positive endexpiratory pressure of 5 cm H2O rendered a partial pressure of oxygen (PaO2) of 179 mm Hg. Due to the many donor risk factors (smoking, poor gas exchange, abnormal chest radiograph, medical history), we decided to further evaluate and treat the lungs with normothermic ex vivo lung perfusion (EVLP) using the previously described Toronto technique (4,6).
After EVLP, lungs were therefore considered acceptable for transplantation. A sample of perfusate solution was collected every hour. Lung biopsy was performed prior to EVLP and at 3 and 6 h after EVLP initiation. HCV virus load was performed by polymerase chain reaction in tissue and perfusate (Abbott RealTime HCV assay; Abbott Park, IL). Perfusate viral load dropped from 26 554 IU/mL in the first hour to 9639 IU/mL for the sixth hour. Moreover, tissue viral load dropped from 49 190 IU/mL prior to EVLP to 3864 IU/mL in the sixth hour.
Patient outcome
Prior to being transferred to the operating room for transplantation, due to severe hypoxemia, the recipient was placed on veno-venous extracorporeal membrane oxygenation (ECMO) using a dual-lumen cannula (Avalon, Maquet, Germany). After single lung transplantation, he was weaned from ECMO on day 4 and lung function was very good, leading to extubation on day 7. HLA antibody testing did not reveal any donor-specific antibodies with a negative T and B flow cytometry crossmatch. No induction immunosuppression was used as routine practice in our program. The patient was placed on the same dose of immunosuppression that he was prior to his re-transplant (tacrolimus, mycophenolate, prednisone). He also received pneumocystis pneumonia prophylaxis with trimethoprimsulfamethoxazole and cytomegalovirus prophylaxis with valganciclovir. The patient recovered gradually and was discharged home 6 weeks after transplantation. No episodes of acute rejection were observed in the first 12 months after transplant. The patient is now 16 months posttransplant. He is completely ambulatory and quality of life is excellent without any functional limitations.
HCV surveillance and treatment
Following the transplant, the donor blood HCV genotype was reported as 1a. HCV RNA 2 weeks posttransplant became positive with a viral load of 1.03E + 6 IU. The patient's health insurer approved ledipasvir/sofosbuvir (Harvoni, Gilead Sciences, Foster City, CA) given the high risk of rapidly progressive HCV infection. Treatment was started 6 weeks posttransplant (4 weeks post viremia detection due to wait time for insurance authorization). At the time, his creatinine was 170 lM/L and glomerular filtration rate was 38 mL/min/1.73 m 2 . Viral load at 1 month postinitiation of therapy was negative. The patient completed 12 weeks of treatment with undetectable HCV RNA, normal liver enzymes, and no significant side effects. Sustained virology response 12 weeks after completion of treatment was achieved. A time course of recipient monitoring for HCV viremia relative to treatment is shown in Figure 1 .
Hepatitis B surveillance
There was no specific monitoring for hepatitis B; however, at 1 year after transplantation, the patient's HBsAb and HBsAg were negative.
Discussion
This case report describes the first known successful DAA treatment of donor-acquired HCV in a lung transplant recipient. Antiviral therapy of HCV has evolved with transition from interferon/ribavirin-based therapy to development of DAA. Interferon/ribavarin/protease inhibitorbased therapy could achieve 60-70% sustained virologic response (SVR) rates but with significant side effects. Interferon-based therapy was found to be suboptimal in heart or lung transplant recipients due to increased incidence of acute allograft rejection (7).
A combination of the DAA drugs ledipasvir, a HCV NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, has been indicated for the treatment of chronic HCV genotype 1, 4, 5, or 6 infections. This therapy leads to SVR of more than 90% in immunocompetent patients with chronic HCV infection with less serious side effects or toxicity as compared to interferonbased therapy (8) . However, this therapy is expensive with a cost of $65 000 USD for 12 weeks of treatment in Canada and $84 000 USD in the United States (list price). Whereas questions have been raised regarding usefulness of these new drugs in immunosuppressed patients, recent clinical trials have demonstrated high effectiveness and good tolerability of treatment in combination with immunosuppressive drugs in liver transplant recipients with HCV recurrence (9) . The most common adverse events were fatigue (30%), diarrhea (28%), and headache (25%). Interruption of treatment was rare. There were no deaths or graft loss, and no net directional changes in the trough levels of tacrolimus or cyclosporine were noted in the study. A recent report of three cases using DAAs for treatment of chronic HCV after lung transplantation (not donor acquired) demonstrated SVR and high tolerability along with a lung immunosuppressive regimen (10) . Since the HCV genotype is usually not known at the time of donor retrieval, the new pangenotypic DAA combination of sofosbuvir/ velpatisvir has further advantages, especially if genotype 3 infection is found after transplantation (11, 12) .
Notably, in our case, viral load in donor lung tissue as well as perfusate decreased significantly during EVLP; however, this reduction did not prevent transmission. In addition, we cannot attribute this effect to the good outcome of this patient.
Conclusion
In conclusion, we demonstrate a successful lifesaving transplantation from a HCV+ donor to a HCVÀ recipient. In the new era of DAA, we believe this practice should be formally evaluated as part of a clinical trial. If proven to be effective, a large new source of donor lungs may become available.
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